This early-phase study is testing a new antibody drug called bexmarilimab in combination with standard cancer therapies. It aims to find a safe dose and see if the combination helps adults with advanced forms of blood cancers like myelodysplastic syndrome (MDS) and acute myeloid …
Phase: PHASE1, PHASE2 • Sponsor: Faron Pharmaceuticals Ltd • Aim: Disease control
Last updated Apr 01, 2026 21:56 UTC